Details of the Drug Combination

General Information of Drug Combination (ID: DCP2VTL)

Drug Combination Name
GSK2194069 BIO-300
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs GSK2194069   DMZ2TD9 BIO-300   DMJ7NVI
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: KBM-7
Zero Interaction Potency (ZIP) Score: 2.45
Bliss Independence Score: 2.45
Loewe Additivity Score: 2.9
LHighest Single Agent (HSA) Score: 2.99

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of GSK2194069
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
GSK2194069 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Fatty acid synthase (FASN) TT7AOUD FAS_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [3]
Rheumatoid arthritis FA20 Phase 1 [4]

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014 Sep;10(9):774-9.
3 Clinical pipeline report, company report or official report of Humanetics.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)